Human Immunodeficiency Virus and Hepatotropic Viruses Co-morbidities As the Inducers of Liver Injury Progression

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2019 Feb 1

PMID 30700937

Citations 28

Authors

Murali Ganesan

Larisa Y Poluektova

Kusum K Kharbanda

Natalia A Osna

Affiliations

Soon will be listed here.

Abstract

Hepatotropic viruses induced hepatitis progresses much faster and causes more liver- related health problems in people co-infected with human immunodeficiency virus (HIV). Although treatment with antiretroviral therapy has extended the life expectancy of people with HIV, liver disease induced by hepatitis B virus (HBV) and hepatitis C virus (HCV) causes significant numbers of non-acquired immune deficiency syndrome (AIDS)-related deaths in co-infected patients. In recent years, new insights into the mechanisms of accelerated fibrosis and liver disease progression in HIV/HCV and HIV/HBV co-infections have been reported. In this paper, we review recent studies examining the natural history and pathogenesis of liver disease in HIV-HCV/HBV co-infection in the era of direct acting antivirals (DAA) and antiretroviral therapy (ART). We also review the novel therapeutics for management of HIV/HCV and HIV/HBV co-infected individuals.

Citing Articles

Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data.

Guo Q, Zhu X, Beeraka N, Zhao R, Li S, Li F Sci Rep. 2024; 14(1):28131.

PMID: 39548154 PMC: 11568312. DOI: 10.1038/s41598-024-77658-2.

YAP mediates HIV-related liver fibrosis.

Spalding V, Fellenstein B, Ahodantin J, Jeyarajan A, Wang Y, Khan S JHEP Rep. 2024; 6(11):101163.

PMID: 39524207 PMC: 11544392. DOI: 10.1016/j.jhepr.2024.101163.

Renal Manifestations of Chronic Hepatitis C: A Review.

Sohal A, Singh C, Bhalla A, Kalsi H, Roytman M J Clin Med. 2024; 13(18).

PMID: 39337023 PMC: 11433393. DOI: 10.3390/jcm13185536.

Plasma proteomic profiles of patients with HIV infection and coinfection with hepatitis B/C virus undergoing anti‑retroviral therapy.

Tarnathummanan C, Soimanee T, Khattiya J, Sretapunya W, Phaonakrop N, Roytrakul S Biomed Rep. 2024; 21(5):155.

PMID: 39268407 PMC: 11391517. DOI: 10.3892/br.2024.1843.

Association of serum lipid profile with liver fibrosis in HCV‑coinfected HIV patients on suppressive anti‑retroviral therapy.

Srisopa S, Pipatsatitpong D, Akekawatchai C Biomed Rep. 2024; 21(4):146.

PMID: 39170754 PMC: 11337153. DOI: 10.3892/br.2024.1834.

References

Herbeuval J, Grivel J, Boasso A, Hardy A, Chougnet C, Dolan M . CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood. 2005; 106(10):3524-31. PMC: 1895067. DOI: 10.1182/blood-2005-03-1243. View

Benhammou J, Dong T, May F, Kawamoto J, Dixit R, Jackson S . Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. Pharmacol Res Perspect. 2018; 6(2):e00379. PMC: 5821896. DOI: 10.1002/prp2.379. View

Alter M, Margolis H, Krawczynski K, Judson F, Mares A, ALEXANDER W . The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992; 327(27):1899-905. DOI: 10.1056/NEJM199212313272702. View

Luetkemeyer A, Wyles D . CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis. Top Antivir Med. 2017; 25(2):84-92. PMC: 5677046. View

Aranzabal L, Casado J, Moya J, Quereda C, Diz S, Moreno A . Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2005; 40(4):588-93. DOI: 10.1086/427216. View

Jo M, Kim T, Seol D, Esplen J, Dorko K, Billiar T . Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000; 6(5):564-7. DOI: 10.1038/75045. View

Koziel M, Peters M . Viral hepatitis in HIV infection. N Engl J Med. 2007; 356(14):1445-54. PMC: 4144044. DOI: 10.1056/NEJMra065142. View

Lacombe K, Bottero J, Lemoine M, Boyd A, Girard P . HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother. 2009; 65(1):10-7. DOI: 10.1093/jac/dkp414. View

Lewin S, Ribeiro R, Avihingsanon A, Bowden S, Matthews G, Marks P . Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology. 2008; 49(4):1113-21. PMC: 2720274. DOI: 10.1002/hep.22754. View

10.

Rohrbach J, Robinson N, Harcourt G, Hammond E, Gaudieri S, Gorgievski M . Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut. 2010; 59(9):1252-8. DOI: 10.1136/gut.2009.205971. View

11.

Repetto M, Reides C, Gomez Carretero M, Costa M, Griemberg G, Llesuy S . Oxidative stress in blood of HIV infected patients. Clin Chim Acta. 1996; 255(2):107-17. DOI: 10.1016/0009-8981(96)06394-2. View

12.

SanMartin R, Tor J, Sanvisens A, Lopez J, Jou A, Muga R . Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. HIV Med. 2013; 15(4):203-12. DOI: 10.1111/hiv.12105. View

13.

Huang X, Liang H, Fan X, Zhu L, Shen T . Liver Damage in Patients with HCV/HIV Coinfection Is Linked to HIV-Related Oxidative Stress. Oxid Med Cell Longev. 2016; 2016:8142431. PMC: 4736998. DOI: 10.1155/2016/8142431. View

14.

Bischoff J, Rockstroh J . Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?. Int J Antimicrob Agents. 2018; 56(1):105527. DOI: 10.1016/j.ijantimicag.2018.08.019. View

15.

Herbein G, Gras G, Khan K, Abbas W . Macrophage signaling in HIV-1 infection. Retrovirology. 2010; 7:34. PMC: 2865443. DOI: 10.1186/1742-4690-7-34. View

16.

Pasarin M, Abraldes J, Liguori E, Kok B, La Mura V . Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction. World J Gastroenterol. 2017; 23(37):6777-6787. PMC: 5645612. DOI: 10.3748/wjg.v23.i37.6777. View

17.

Revill P, Littlejohn M, Ayres A, Yuen L, Colledge D, Bartholomeusz A . Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS. 2007; 21(13):1701-10. DOI: 10.1097/QAD.0b013e32826fb305. View

18.

Mallet V, Vallet-Pichard A, Pol S . The impact of human immunodeficiency virus on viral hepatitis. Liver Int. 2011; 31 Suppl 1:135-9. DOI: 10.1111/j.1478-3231.2010.02394.x. View

19.

Colin J, Cazals-Hatem D, Loriot M, Martinot-Peignoux M, Pham B, Auperin A . Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999; 29(4):1306-10. DOI: 10.1002/hep.510290447. View

20.

Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C . Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016; 16(7):797-808. DOI: 10.1016/S1473-3099(15)00485-5. View